J Korean Med Sci.  2005 Dec;20(6):966-970. 10.3346/jkms.2005.20.6.966.

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study

• Baek JH
• Kim JG
• Sohn SK
• Kim DH
• Lee KB
• Song HS
• Kwon KY
• Do YR
• Ryoo HM
• Bae SH
• Park KU
• Kim MK
• Lee KH
• Hyun MS
• Chung HY
• Yu W

• KMID: 2157746
• DOI: http://doi.org/10.3346/jkms.2005.20.6.966

Abstract

The current phase II study was conducted to evaluate the response rate and safety of a combination regimen of biweekly irinotecan plus cisplatin in pretreated patients with advanced gastric cancer. Patients with previously treated metastatic or recurrent gastric cancer received intravenous irinotecan 70 mg/m2 and cisplatin 30 mg/m2 on day 1 and 15 every 4-week cycle. Thirty-two patients were enrolled in the current study. Of these, 31 patients were assessable for efficacy and all for toxicity. No complete response and 5 partial responses were confirmed, giving an overall response rate of 15.6% (95% CI; 2.3-28.9%). The median time to progression and median overall survival for all patients was 113 days and 184 days, respectively. Grade 3/4 neutropenia occurred in 6 patients (18.8%), yet no febrile neutropenia was observed. In addition, grade 3 anorexia was observed in 4 patients (12.5%) and grade 3 diarrhea occurred in 2 patients (6.2%). The combination chemotherapy of biweekly irinotecan and cisplatin was found to be moderately effective and well tolerated in pretreated patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important second-line treatment option for advanced gastric cancer.

Keyword

irinotecan; Cisplatin; Drug Therapy; Stomach Neoplasms

MeSH Terms

Adolescent
Adult
Aged
Antineoplastic Agents/*administration and dosage/adverse effects
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow/drug effects
Camptothecin/administration and dosage/adverse effects/*analogs and derivatives
Cisplatin/*administration and dosage/adverse effects
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local/drug therapy
Stomach Neoplasms/*drug therapy/secondary

Figure

• 

  Fig. 1 Time to progression for all patients.

• 

  Fig. 2 Overall survival for all patients.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Korea Gastric Cancer Association. Nationwide gastric cancer report in Korea. J Korean Gastric Cancer Assoc. 2002. 2:105–114.

3. Choi NK, Youn KE, Heo DS, Lee SM, Kim Y, Park BJ. Stomach cancer incidence, mortality and survival rate in Korean Elderly Pharmacoepidemiologic Cohort (KEPEC) in 1994-1998. Cancer Res Treat. 2003. 35:383–390.

4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993. 72:37–41.

5. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994. 5:189–190.

6. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer. 1995. 71:587–591.

7. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol. 2003. 14:ii49–ii55.

8. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989. 49:5077–5082.

9. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994. 86:836–842.

10. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother. 1994. 21:1033–1038.

11. Sato A, Kurihara M, Matsukawa M, Shimada K, Yamazaki T, Nakamachi M, Koda T. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol. 2001. 47:380–384.

12. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999. 17:319–323.

13. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 2001. 15:52–54.

14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000. 92:205–216.

15. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 2002. 16:16–18.

16. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003. 14:383–387.

17. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol. 2004. 15:64–69.

18. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004. 34:8–13.

19. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep. 2002. 9:89–92.

20. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003. 14:Suppl 2. ii41–ii44.